Search
Florquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052,L64053] It is the second fluorine-18 tau PET imaging agent approved in the United States, after flortaucipir (Tauvid), which was approved in 2020.[L64054,L14114] … [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease
Ademetionine
go.drugbank.com/drugs/DB00118ApprovedInvestigationalNutraceuticalIt possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
Synonyms: SAM-e, L-S-AdenosylmethionineMixtures: HEPATAMINE %8 500 ML(SETLI), HEPATAMINE %8 500 ML(SETSIZ)Tepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalAnderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma,[A228053] gastric cancers,[A228033] non-small cell lung cancer, and hepatocellular carcinoma. … Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February
Categories: Proto-Oncogene Proteins c-met, antagonists & inhibitorsZinc acetate
go.drugbank.com/drugs/DB14487ApprovedInvestigationalMixtures: Johnson and Johnson First Aid All Purpose 160 CT, NUTRIFLEX LIPID PLUS INFUZYONLUK EMULSIYON, 2500 MLPiflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationallevels roughly 1000-fold greater than elsewhere in the body, and even higher in prostate cancer tissue. … [A235169] As such, it has become a desirable target for PET imaging of prostate cancer tissues.
Tafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigational[A35677] It was FDA approved on July 20, 2018.[L3770] … [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalThe NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636] … [A18696] In 2016, it was granted approval to treat primary biliary cholangitis in combination with [ursodeoxycholic acid], which was previously the mainstay treatment for this condition.
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized … [L740] It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34.
Flurpiridaz F-18
go.drugbank.com/drugs/DB18773Approved[A264519] Flurpiridaz F-18 is an analog of pyridaben, a mitochondrial complex 1 (MC-1) inhibitor.[L51659] … Flurpiridaz F-18 is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI), which is an imaging process used in patients with known or suspected
Pancrelipase lipase
go.drugbank.com/drugs/DB13147ApprovedInvestigational[A32748] The pancrelipase mixture, including pancrelipase lipase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]
Mixtures: Pancrease Mt 10, Pancrease Mt 20Products: Formula C & E